ES2324876T3 - Composiciones y metodos para el diagnostico de tumores. - Google Patents

Composiciones y metodos para el diagnostico de tumores. Download PDF

Info

Publication number
ES2324876T3
ES2324876T3 ES05019849T ES05019849T ES2324876T3 ES 2324876 T3 ES2324876 T3 ES 2324876T3 ES 05019849 T ES05019849 T ES 05019849T ES 05019849 T ES05019849 T ES 05019849T ES 2324876 T3 ES2324876 T3 ES 2324876T3
Authority
ES
Spain
Prior art keywords
acid sequence
amino acid
polypeptide
identity
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05019849T
Other languages
English (en)
Inventor
David Botstein
Audrey Goddard
Austin L Gurney
Margaret Ann Roy
Colin K Watanabe
William I Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2324876T3 publication Critical patent/ES2324876T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Método para determinar la presencia de un polipéptido PR04407 en una muestra sospechosa de contener dicho polipéptido, comprendiendo dicho método exponer la muestra a un anticuerpo anti-PR04407 y determinar la unión de dicho anticuerpo a dicho polipéptido en dicha muestra; donde dicha muestra comprende células de pulmón, colon, mama o paratiroides obtenidas de un individuo del que se sospecha que tiene crecimiento o proliferación de células neoplásicas, y donde dicho polipéptido PRO4407 es un polipéptido: a) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con una secuencia de aminoácidos seleccionada entre el grupo que consiste en la secuencia de aminoácidos mostrada en la Figura 2 (SEC ID Nº: 47); b) que da una valoración al menos el 60% de positivos cuando se compara con una secuencia de aminoácidos seleccionada entre el grupo que consiste en la secuencia de aminoácidos mostrada en la Figura 2 (SEC ID Nº: 47); c) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con una secuencia de aminoácidos codificada por la secuencia codificante de longitud completa de la secuencia de ácido nucleico DNA 92264- 2616 depositada con el número de entrada en la ATCC 203969; d) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con el polipéptido mostrado en la Figura 2 (SEC ID Nº: 47), que carece de su péptido señal asociado; e) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 47), con su péptido señal asociado; o f) que tiene al menos el 80% de identidad en la secuencia de aminoácidos con un dominio extracelular del polipéptido mostrado en la Figura 2 (SEC ID Nº: 47), que carece de su péptido señal asociado donde la identidad en la secuencia se calcula usando el programa ALIGN-
ES05019849T 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores. Expired - Lifetime ES2324876T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
ES2324876T3 true ES2324876T3 (es) 2009-08-18

Family

ID=29215742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05019849T Expired - Lifetime ES2324876T3 (es) 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores.
ES05019847T Expired - Lifetime ES2329689T3 (es) 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05019847T Expired - Lifetime ES2329689T3 (es) 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores.

Country Status (9)

Country Link
EP (6) EP1634892A3 (es)
JP (7) JP2003525585A (es)
KR (5) KR100543857B1 (es)
AT (2) ATE427319T1 (es)
AU (4) AU773055C (es)
CA (1) CA2367334A1 (es)
DE (2) DE69940681D1 (es)
ES (2) ES2324876T3 (es)
WO (1) WO2000053750A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914130B2 (en) * 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2002533109A (ja) * 1998-12-23 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトＢｒａｉｎｉａｃ−５
EP1224201A4 (en) * 1999-10-29 2005-03-02 Human Genome Sciences Inc 32 HUMAN SECRETED PROTEINS
WO2001066720A1 (fr) * 2000-03-10 2001-09-13 Toshio Kitamura Genes de souris d'origine adipocyte
US20020123475A1 (en) * 2000-06-30 2002-09-05 Leiby Kevin R. 32626, a novel human UDP-glycosyltransferase and uses thereof
AU2001271973A1 (en) * 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1399564A2 (en) * 2001-02-16 2004-03-24 Incyte Genomics, Inc. Drug metabolizing enzymes
GB0110273D0 (en) * 2001-04-26 2001-06-20 Inpharmatica Ltd Novel proteins
JP2004147542A (ja) * 2002-10-30 2004-05-27 National Institute Of Advanced Industrial & Technology 糖転移酵素及びそれをコードする核酸、並びに該核酸を用いた癌組織の検出方法
US20110097330A1 (en) * 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
JP2009131151A (ja) * 2006-02-28 2009-06-18 Osaka Univ ＰＩＬＲαと結合するポリペプチド、およびそれをコードするポリヌクレオチド、並びにその利用
JP2009537154A (ja) 2006-05-18 2009-10-29 モレキュラー プロファイリング インスティテュート， インコーポレイテッド 疾患状態に対する個別化された医学的介入を決定するためのシステムおよび方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
WO2015010615A1 (zh) * 2013-07-23 2015-01-29 四川大学华西医院 一种重组trail蛋白及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976790A (en) * 1992-03-04 1999-11-02 The Regents Of The University Of California Comparative Genomic Hybridization (CGH)
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
CA2137822C (en) * 1992-06-26 2009-01-20 Arnold J. Levine Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
AU8404598A (en) * 1997-07-16 1999-02-10 Human Genome Sciences, Inc. 64 human secreted proteins
JP2002508182A (ja) * 1997-12-17 2002-03-19 ジェンセット 分泌タンパク質の伸長ｃＤＮＡ
EP1044210A1 (en) * 1997-12-18 2000-10-18 Human Genome Sciences, Inc. Human dendriac and brainiac-3
JP2002508167A (ja) * 1997-12-18 2002-03-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １１０個のヒト分泌タンパク質
NZ507435A (en) * 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
JP2002516082A (ja) * 1998-05-29 2002-06-04 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト膜貫通タンパク質
JP2002520050A (ja) * 1998-07-15 2002-07-09 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７１個のヒト分泌タンパク質
WO2000029448A2 (en) * 1998-11-17 2000-05-25 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
KR100468978B1 (ko) * 1998-12-16 2005-02-02 제넨테크, 인크. 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
JP2002533109A (ja) * 1998-12-23 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトＢｒａｉｎｉａｃ−５
WO2000041539A2 (en) * 1999-01-12 2000-07-20 Zymogenetics, Inc. Human beta-1,3-galactosyltransferase homolog, znssp6
DE69926415T2 (de) * 1999-02-10 2006-05-24 Genentech, Inc., South San Francisco Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
JP4551041B2 (ja) * 1999-06-29 2010-09-22 協和発酵キリン株式会社 有用ポリペプチド
AU6069300A (en) * 1999-07-02 2001-01-22 Chiron Corporation Novel human genes and gene expression products
JP2002017375A (ja) * 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 全長ｃＤＮＡ合成用プライマー、およびその用途
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
AU7680300A (en) * 1999-08-18 2001-03-13 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Human dna sequences
WO2001018046A2 (en) * 1999-09-10 2001-03-15 Corixa Corporation Ovarian tumor sequences and methods of use therefor
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides

Also Published As

Publication number Publication date
JP2003274977A (ja) 2003-09-30
EP1634892A3 (en) 2006-06-21
EP1159422A1 (en) 2001-12-05
EP1642967A2 (en) 2006-04-05
JP2003274978A (ja) 2003-09-30
JP2003274979A (ja) 2003-09-30
EP1642907A2 (en) 2006-04-05
EP1634892A2 (en) 2006-03-15
AU773055C (en) 2004-12-02
CA2367334A1 (en) 2000-09-14
EP1642907B1 (en) 2009-04-01
AU2004201769A1 (en) 2004-05-27
AU773055B2 (en) 2004-05-13
KR100473551B1 (en) 2005-03-14
EP1642967A3 (en) 2006-07-26
JP2009039097A (ja) 2009-02-26
KR20050004773A (ko) 2005-01-12
ATE427319T1 (de) 2009-04-15
KR20040088077A (ko) 2004-10-15
AU2004201760B2 (en) 2007-07-19
EP1642906A2 (en) 2006-04-05
EP1642968A3 (en) 2006-06-21
AU2004201769B2 (en) 2007-07-19
ES2329689T3 (es) 2009-11-30
KR20040077790A (ko) 2004-09-06
DE69940681D1 (de) 2009-05-14
EP1642968B1 (en) 2009-08-12
KR100517848B1 (en) 2005-09-30
JP2009000114A (ja) 2009-01-08
WO2000053750A1 (en) 2000-09-14
DE69941273D1 (de) 2009-09-24
KR100566839B1 (ko) 2006-04-03
AU3107700A (en) 2000-09-28
KR20020008123A (ko) 2002-01-29
AU2004201759A1 (en) 2004-05-20
EP1642968A2 (en) 2006-04-05
AU2004201760A1 (en) 2004-05-20
KR20040073588A (ko) 2004-08-19
EP1642906A3 (en) 2006-07-26
JP2003525585A (ja) 2003-09-02
KR100543857B1 (ko) 2006-01-23
AU2004201759B2 (en) 2007-07-19
JP2003274980A (ja) 2003-09-30
ATE439431T1 (de) 2009-08-15
EP1642907A3 (en) 2006-06-21
KR100473550B1 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
ES2324876T3 (es) Composiciones y metodos para el diagnostico de tumores.
ES2525677T3 (es) Celulasas, genes que las codifican y usos de las mismas
ATE321849T1 (de) Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
CA2395699A1 (en) NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
JP2005522999A5 (es)
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE427354T1 (de) Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
NO20001668D0 (no) Anvendelse av et DNA-fragment, samt komplementære kjeder, derivater og deler derav
BR9806318A (pt) Polipeptìdeo pde8, polinucleotìdeo codificando o mesmo, dna, polinucleotìdeo anti-sentido, construção de expressão, célula hospedeira, processo para produzir um polipeptìdeo pde8, anticorpo, hibridoma, anticorpo anti-idiotipo, processo para identificar um composto parceiro de ligação espefcìfico de um polipeptìdeo pde8a, e de polinucleotìdeo pde8a, composto, e, composição.
AR014233A1 (es) Metodo para el control del perforante europeo del maiz (ostrinia nubilalis)
ATE299182T1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
PL327066A1 (en) Method of diagnosing and treating squamous cell carcinomas
AU8503898A (en) Monospecific antibody reactive with fibrinogen and fibrinopeptide
JP2005535289A5 (es)
DE60331882D1 (de) Antikörper zur Identifizierung und/oder Isolierung von wenigstens einer Zellpopulation ausgewählt aus hämatopoetischen Stammzellen, neuronalen Stammzellen, progenitoren neuronalen Zellen, Mesenchym-Stammzellen und mesenchym-progenitoren Stammzellen
JP2005525112A5 (es)
JP2005516604A5 (es)
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
JP2005508169A5 (es)
ATE318933T1 (de) Nukleinsäurefragmente zur identifizierung von dechlorierenden bakterien
AR012252A1 (es) Un metodo para identificar agentes que se unen a un receptor de toxina bt y que bloquean la union de una toxina bt; un anticuerpo aislado; una proteinareceptora aislada de toxina bt y un metodo para producirla
JP2005513422A5 (es)
JP2005508633A5 (es)